Cargando…

2375. Skin and Soft-Tissue Infections in Patients With Obesity or Heart Failure

BACKGROUND: Skin and soft-tissue infections (SSTIs) are among the most common infectious diseases-related hospitalizations. Although existing literature supports durations of 5–7 days, treatment durations commonly exceed 10–14 days often driven by perceived lack of resolution and risk of relapse. Ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Ihm, Claudia, Sutton, Jesse, Timbrook, Tristan T, Spivak, Emily
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255657/
http://dx.doi.org/10.1093/ofid/ofy210.2028
_version_ 1783373993003188224
author Ihm, Claudia
Sutton, Jesse
Timbrook, Tristan T
Spivak, Emily
author_facet Ihm, Claudia
Sutton, Jesse
Timbrook, Tristan T
Spivak, Emily
author_sort Ihm, Claudia
collection PubMed
description BACKGROUND: Skin and soft-tissue infections (SSTIs) are among the most common infectious diseases-related hospitalizations. Although existing literature supports durations of 5–7 days, treatment durations commonly exceed 10–14 days often driven by perceived lack of resolution and risk of relapse. Obesity and heart failure (HF) have been associated with increased risk for treatment failure of SSTIs. We aimed to evaluate practice patterns for SSTIs in patients with either obesity or HF and whether short durations of therapy (≤ 8 days) are associated with treatment failure. METHODS: We performed a retrospective cohort study at the Salt Lake City VA Medical Center including a subset of inpatients between January 1, 2006 and December 30, 2016 with SSTIs based on international classification of diseases (ICD) coding and either HF or obesity. Charts were manually reviewed to collect demographic, comorbidity, severity of illness, microbiology, and treatment data. Patients who were treated with a short course (≤8 days) vs. a long course (>8 days) of antimicrobial therapy were evaluated. Primary outcome included treatment failure within 30 days defined as extending therapy, changing or adding antimicrobials, reinitiating therapy or drainage of an abscess after the end of the initial treatment course. Secondary outcomes assessed were length of stay, 30-day readmission, and 30-day mortality. RESULTS: 466 randomly selected charts were reviewed and 130 patients were included. 128 patients (98%) were male. 32% of patients had HF, 87% obesity and 47% diabetes. 5 patients were admitted to the ICU. Median treatment duration was 12 days [IQR 9–15]. 27 (21%) received ≤ 8 days of antibiotics and 103 (79%) received > 8 days. 5/27 (19%) patients in the short treatment group experienced treatment failure vs. 26/103 (25%) in the long treatment group (P = 0.466). Median length of stay was 2 days [IQR 2–3] vs. 3 days [IQR 2–5] in the short vs. long treatment group, respectively (P = 0.002). There was no difference in 30-day readmission or 30-day mortality between the two groups. CONCLUSION: Commonly prescribed antibiotic durations for SSTIs in patients with obesity and/or HF often exceeded 8 days. Short treatment duration does not appear to be associated with treatment failure, highlighting an opportunity for antimicrobial stewardship intervention. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6255657
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62556572018-11-28 2375. Skin and Soft-Tissue Infections in Patients With Obesity or Heart Failure Ihm, Claudia Sutton, Jesse Timbrook, Tristan T Spivak, Emily Open Forum Infect Dis Abstracts BACKGROUND: Skin and soft-tissue infections (SSTIs) are among the most common infectious diseases-related hospitalizations. Although existing literature supports durations of 5–7 days, treatment durations commonly exceed 10–14 days often driven by perceived lack of resolution and risk of relapse. Obesity and heart failure (HF) have been associated with increased risk for treatment failure of SSTIs. We aimed to evaluate practice patterns for SSTIs in patients with either obesity or HF and whether short durations of therapy (≤ 8 days) are associated with treatment failure. METHODS: We performed a retrospective cohort study at the Salt Lake City VA Medical Center including a subset of inpatients between January 1, 2006 and December 30, 2016 with SSTIs based on international classification of diseases (ICD) coding and either HF or obesity. Charts were manually reviewed to collect demographic, comorbidity, severity of illness, microbiology, and treatment data. Patients who were treated with a short course (≤8 days) vs. a long course (>8 days) of antimicrobial therapy were evaluated. Primary outcome included treatment failure within 30 days defined as extending therapy, changing or adding antimicrobials, reinitiating therapy or drainage of an abscess after the end of the initial treatment course. Secondary outcomes assessed were length of stay, 30-day readmission, and 30-day mortality. RESULTS: 466 randomly selected charts were reviewed and 130 patients were included. 128 patients (98%) were male. 32% of patients had HF, 87% obesity and 47% diabetes. 5 patients were admitted to the ICU. Median treatment duration was 12 days [IQR 9–15]. 27 (21%) received ≤ 8 days of antibiotics and 103 (79%) received > 8 days. 5/27 (19%) patients in the short treatment group experienced treatment failure vs. 26/103 (25%) in the long treatment group (P = 0.466). Median length of stay was 2 days [IQR 2–3] vs. 3 days [IQR 2–5] in the short vs. long treatment group, respectively (P = 0.002). There was no difference in 30-day readmission or 30-day mortality between the two groups. CONCLUSION: Commonly prescribed antibiotic durations for SSTIs in patients with obesity and/or HF often exceeded 8 days. Short treatment duration does not appear to be associated with treatment failure, highlighting an opportunity for antimicrobial stewardship intervention. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6255657/ http://dx.doi.org/10.1093/ofid/ofy210.2028 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Ihm, Claudia
Sutton, Jesse
Timbrook, Tristan T
Spivak, Emily
2375. Skin and Soft-Tissue Infections in Patients With Obesity or Heart Failure
title 2375. Skin and Soft-Tissue Infections in Patients With Obesity or Heart Failure
title_full 2375. Skin and Soft-Tissue Infections in Patients With Obesity or Heart Failure
title_fullStr 2375. Skin and Soft-Tissue Infections in Patients With Obesity or Heart Failure
title_full_unstemmed 2375. Skin and Soft-Tissue Infections in Patients With Obesity or Heart Failure
title_short 2375. Skin and Soft-Tissue Infections in Patients With Obesity or Heart Failure
title_sort 2375. skin and soft-tissue infections in patients with obesity or heart failure
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255657/
http://dx.doi.org/10.1093/ofid/ofy210.2028
work_keys_str_mv AT ihmclaudia 2375skinandsofttissueinfectionsinpatientswithobesityorheartfailure
AT suttonjesse 2375skinandsofttissueinfectionsinpatientswithobesityorheartfailure
AT timbrooktristant 2375skinandsofttissueinfectionsinpatientswithobesityorheartfailure
AT spivakemily 2375skinandsofttissueinfectionsinpatientswithobesityorheartfailure